Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.

Tefferi, A; Lasho, T L; Finke, C; Belachew, A A; Wassie, E A; Ketterling, R P; Hanson, C A; Pardanani, A

Tefferi, A; Lasho, T L; Finke, C; Belachew, A A; Wassie, E A; Ketterling, R P; Hanson, C A; Pardanani, A.

Affiliation

Tefferi A; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Lasho TL; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Finke C; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Belachew AA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Wassie EA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Ketterling RP; Division of Cytogenetics, Mayo Clinic, Rochester, MN, USA.
Hanson CA; Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Pardanani A; Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Leukemia ; 28(7): 1568-70, 2014 Jul.

Article in En | MEDLINE | ID: mdl-24569778

Subject(s)

Calreticulin/genetics; Mutation; Primary Myelofibrosis/diagnosis; Primary Myelofibrosis/genetics; Aged; Aged, 80 and over; Female; Humans; Janus Kinase 2/genetics; Male; Middle Aged; Phenotype; Primary Myelofibrosis/mortality; Prognosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Calreticulin / Primary Myelofibrosis / Mutation Type of study: Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2014 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google